We should see movement in the stock price in March. Should be in the $10-$12 range by the end of March.
2/26/2015 Roth Capital Initiated Coverage Ohr Pharmaceutical (OHRP) Buy $ $30.00
2/11/2015 Brean Capital Jonathan Aschoff Reiterated Rating Ohr Pharmaceutical (OHRP) Buy $34.00
2/2/2015 Chardan Capital Initiated Coverage OHR Pharmaceutical Inc (OHRP) $20.00
12/23/2014 Brean Capital Jonathan Aschoff Initiated Coverage OHR Pharmaceutical Inc (OHRP) $34.00
6/25/2014 Brean Capital Boost Price Target OHR Pharmaceutical Inc (OHRP) $34.00
6/24/2014 Brean Capital Boost Price Target OHR Pharmaceutical Inc (OHRP) $34.00 Less
so the "thumb down" votes mean disagreement with the presentation. LOL confused losers.
Yes "We are building a self-sustaining biopharmaceutical company" (The first slide in the body of the investors' presentation! ) "2015 Corporate Goal: Acquire at least one external asset" (slide #83). Does that sound like buyout talk?
Yes "We are building a self-sustaining biopharmaceutical company" (The first slide in the body of the investors' presentation! ) "2015 Corporate Goal: Acquire at least one external asset" (slide #83). Does that sound like buyout talk? LOL at the penny-wise pound-foolish losers.
unless they are deluded or BS artists (there's a history of that going back to the Allen Iplex lawsuit days), management making point through presentation that Insmed not for sale. instead, looking for property.
"in encouragement of their continued service to the Company." must have been some great discussions during the board meeting. perhaps not fun to be working at ADES during last few years.
i'm no genius, but really ...
On March 3, 2015, the Compensation Committee of the Board of Directors of Advanced Emissions Solutions, Inc. (the "Company") approved retention bonuses (the "Retention Bonuses") for the following executive officers of the Company:
(i) Jonathan Lagarenne, Executive Vice President; (ii) Christine Amrhein, General Counsel and Secretary; and (iii) Sharon Sjostrom, Chief Technology Officer. Under the terms of the Retention Bonuses, the Company will pay each of these executives a cash bonus in the amount of $50,000, as long as such executive is employed by the Company or any related entity of the Company on December 31, 2015, with such bonus to be paid on or before March 15, 2016. The Retention Bonuses were approved in recognition of the value that each executive officer adds to the Company and in encouragement of their continued service to the Company.
5 X's current price? if wishing could make it so ... history and evidence (if those concepts matter) suggest that 50% over current price would be acceptable to big holders (who would decide) for smaller players. "potential" counts, but only so much. INSM's option volume yesterday was heavy (nearly 1500 contracts vs 177 average); 100 today in first hour of trading.
by coincidence, Celldex was a spinoff from Medarex a few years ago. Medarex was "stolen" from shareholders in a low-priced buyout when its shareprice was depressed.
much greater number than is typical. probably associated with buyout speculation.
i've been through enough biotech buyouts as a shareholder to know that long-time investors are almost always disappointed in the selling price. fly-by-night lawsuits abound. Investors here who are hoping for a buyout now rather than a longer ramp-up to real fulfillment of INSM's potential (whatever it is) are short-sighted fools.
more option activity today (350 April 22 calls purchased at the ask), but still nothing significant compared to what would be expected with substantial buyout anticipation. also, talk of offers of 3x's current price is ridiculous.